Connection
Lisa Bero to Cost-Benefit Analysis
This is a "connection" page, showing publications Lisa Bero has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.237 |
|
|
|
-
Anglemyer AT, Krauth D, Bero L. Industry sponsorship and publication bias among animal studies evaluating the effects of statins on atherosclerosis and bone outcomes: a meta-analysis. BMC Med Res Methodol. 2015 Mar 06; 15:12.
Score: 0.105
-
Krauth D, Anglemyer A, Philipps R, Bero L. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. PLoS Biol. 2014 Jan; 12(1):e1001770.
Score: 0.097
-
Hill SR, Bero L, McColl G, Roughead E. Expensive medicines: ensuring objective appraisal and equitable access. Bull World Health Organ. 2015 Jan 01; 93(1):4.
Score: 0.026
-
Moynihan R, Bero L, Ross-Degnan D, Henry D, Lee K, Watkins J, Mah C, Soumerai SB. Coverage by the news media of the benefits and risks of medications. N Engl J Med. 2000 Jun 01; 342(22):1645-50.
Score: 0.009